Skip to content

Alumis Inc. ALMS EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Amgen logo
AmgenAMGN
$3.34+4.4%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$1.18-45.7%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$1.69-109%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$0.85-3.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$0.05+126%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s EPS (diluted)?
Alumis Inc. (ALMS) reported EPS (diluted) of -$0.74 in Q1 2026.
How has Alumis Inc.'s EPS (diluted) changed year-over-year?
Alumis Inc.'s EPS (diluted) increased by 59.3% year-over-year, from -$1.82 to -$0.74.
What is the long-term trend for Alumis Inc.'s EPS (diluted)?
Over 2 years (2023 to 2025), Alumis Inc.'s EPS (diluted) has grown at a -79.4% compound annual growth rate (CAGR), from -$72.08 to -$3.05.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.